Package Leaflet: Information for the User
Rivaroxaban Teva 2.5 mg film-coated tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
You have been prescribed rivaroxaban because
You will be prescribed rivaroxaban along with another medication. Your doctor will also instruct you to take:
or
You will be prescribed rivaroxaban along with another medication. Your doctor will also instruct you to take aspirin.
In some cases, if you are administered rivaroxaban after an intervention to open a narrowed or blocked artery in the leg to restore blood flow, your doctor may also prescribe clopidogrel for you to take in addition to aspirin for a short period of time.
This medication contains the active substance rivaroxaban, which belongs to a group of medications called antithrombotic agents. It works by blocking a clotting factor (factor Xa) and thus reducing the tendency of blood to form clots.
Do not take Rivaroxaban Teva
Do not take this medication and inform your doctor if any of these circumstances apply to you.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication.
Rivaroxaban should not be used in combination with other medications that reduce blood clotting, other than aspirin or clopidogrel/ticlopidine, such as prasugrel or ticagrelor.
Be careful with Rivaroxaban Teva
Tell your doctor if you have any of these situationsbefore taking this medication. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If you need surgery:
Children and adolescents
Rivaroxaban 2.5 mg tablets are not recommended for children and adolescents under 18 years of age. There is not enough information about its use in children and adolescents.
Other medications and Rivaroxaban Teva
Tell your doctor or pharmacist if you are taking, have recently taken, or may take any other medication, including those purchased without a prescription.
If you are taking:
If any of these circumstances apply to you, tell your doctor before taking this medication, as the effect of rivaroxaban may be increased. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If your doctor considers that you have a higher risk of developing a stomach or intestinal ulcer, they may recommend that you use a preventive treatment in addition.
If any of these circumstances apply to you, tell your doctor before taking this medication, as the effect of rivaroxaban may be reduced. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
Pregnancy and breastfeeding
Do not take this medication if you are pregnant or breastfeeding. If there is any possibility that you may become pregnant, use a reliable contraceptive while taking rivaroxaban. If you become pregnant while taking this medication, inform your doctor immediately, who will decide how you should be treated.
Driving and using machines
This medication may cause dizziness (common side effect) or fainting (uncommon side effect) (see section 4, "Possible side effects"). You should not drive, ride a bicycle, or use tools or machines if you are affected by these symptoms.
This medicationcontains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medicationcontains sodium
This medication contains less than 23 mg of sodium (1 mmol) per tablet; this is, essentially "sodium-free".
Follow the instructions for administration of this medication exactly as indicated by your doctor. If you are unsure, consult your doctor or pharmacist again.
What dose to take
The recommended dose is one 2.5 mg tablet twice a day. Take this medication at the same time every day (e.g., one tablet in the morning and one in the evening). This medication can be taken with or without food.
If you have difficulty swallowing the tablet whole, consult your doctor about other ways to take this medication. The tablet can be crushed and mixed with water or apple sauce, immediately before taking it.
If necessary, your doctor may also administer the crushed rivaroxaban tablet through a gastric tube.
This medication will not be prescribed to you alone.
Your doctor will instruct you to take aspirin as well. If you receive this medication after an acute coronary syndrome, your doctor may also instruct you to take clopidogrel or ticlopidine.
If you are administered rivaroxaban after an intervention to open a narrowed or blocked artery in the leg to restore blood flow, your doctor may also prescribe clopidogrel for you to take in addition to aspirin for a short period of time.
Your doctor will instruct you on the dose to take (usually between 75 and 100 mg of aspirin per day, or a dose of 75 to 100 mg of aspirin plus a daily dose of 75 mg of clopidogrel or a standard daily dose of ticlopidine).
When to start treatment with Rivaroxaban Teva
Treatment with this medication should be started as soon as possible, once the acute coronary syndrome has been stabilized, i.e., from 24 hours after hospital admission and when parenteral anticoagulant treatment (by injection) is finished.
Your doctor will instruct you on when to start treatment with this medication if you have been diagnosed with coronary artery disease or peripheral artery disease.
Your doctor will decide how long you should continue treatment.
If you take more Rivaroxaban Teva than you should
Call your doctor immediately if you have taken too many rivaroxaban tablets. Taking too much rivaroxaban increases the risk of bleeding.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Rivaroxaban Teva
Do not take more than one tablet in a single day to make up for a missed dose. If you forget to take a dose, take the next tablet at the usual time.
If you interrupt treatment with Rivaroxaban Teva
Take this medication regularly for the time indicated by your doctor.
Do not interrupt treatment with this medication without talking to your doctor first. If you stop taking this medication, you may increase your risk of having another myocardial infarction, a stroke, or dying from a heart or blood vessel disease.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Like other similar medicines for reducing blood clot formation, this medicine can cause bleeding that can put the patient's life at risk. Excessive bleeding can cause a sudden drop in blood pressure (shock). In some cases, the bleeding may not be evident.
Inform your doctor immediately if you experience any of the following symptoms:
Your doctor will decide whether to keep you under closer observation or change your treatment.
The frequency of these adverse effects is very rare (up to 1 in 10,000).
The frequencies of severe allergic reactions are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic edema; may affect up to 1 in 100 people)
General list of possible adverse effects:
Frequent(may affect up to 1 in 10 patients):
Uncommon(may affect up to 1 in 100 patients):
Rare(may affect up to 1 in 1,000 patients):
Very rare(may affect up to 1 in 10,000 people)
Frequency not known(frequency cannot be estimated from available data):
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Medicines Monitoring System for Human Use: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging and on each blister after "CAD" or "EXP". The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Crushed tablets
Crushed tablets are stable in water or apple puree for up to 4 hours.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE point in your pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Rivaroxaban Teva
Tablet core: sodium lauryl sulfate, lactose monohydrate, hypromellose, sodium croscarmellose, and magnesium stearate.
Tablet coating: partially hydrolyzed polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol 3350, talc (E553b), and yellow iron oxide (E172).
Appearance of the product and package contents
Rivaroxaban Teva 2.5 mg film-coated tablets are yellow, round, approximately 8 mm in diameter, and have "T" engraved on one side and "2R" on the other.
They are available in:
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Teva GmbH
Graf-Arco-Str. 3
Ulm, 89079
Germany
Manufacturer
Balkanpharma - Dupnitsa AD
3, Samokovsko Shosse Str.
BG-2600 DUPNITSA
Bulgaria
or
Actavis Group PTC ehf
Dalshraun 1, Hafnarfjoerdur
220, Iceland
Local representative
Teva Pharma, S.L.U.
C/Anabel Segura, 11 Edificio Albatros B, 1ª Planta
Alcobendas, 28108 Madrid (Spain)
Date of last revision of this leaflet:November 2023
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
You can access detailed and updated information about this medicine by scanning the QR code included in the packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/85821/P_85821.html